LICENSE AGREEMENT WITH UNIVERSITY OF MICHIGAN


                                                    

                                                                              
                                                                        EXHIBIT
      10.8

    LICENSE
      AGREEMENT

    University
      of Michigan Files 1175, 1356, 1442, 1442d1, 1442d3, 

    1543,
      1543d1, 1720, 2044 and 2115

    


    


    This
      Agreement is effective as of
      May
      24,
      2007
      (the
      "Effective Date"), between Quick-Med Technologies, Inc. ("LICENSEE") having
      the
      address in Article 13 below, and the Regents of the University of Michigan,
      a
      constitutional corporation of the State of Michigan ("MICHIGAN"). LICENSEE
      and
      MICHIGAN agree as follows:

    


    


    ARTICLE
      1 - DEFINITIONS 

    


    1.1 “AFFILIATE”
      means any company, corporation, association or business entity that is
      controlled by, is in control of, or is under common control with a Party. The
      term “control” shall mean a greater than fifty percent (50%) ownership of issued
      and outstanding voting interests in a corporation, limited liability company,
      partnership or other legal entity, or greater than fifty percent (50%)
ownership
      interest in a corporation, limited liability company, partnership or other
      legal
      entity, directly or indirectly.

    


    1.2
       “COMBINATION
      PRODUCT” means a combination or bundled product that is sold at a single price
      by LICENSEE, an AFFILIATE or a SUBLICENSEE and that includes: (a) a LICENSED
      PRODUCT or LICENSED PROCESS and (b) another product or process that is not
      covered by the PATENT RIGHTS.

    


    1.3 “EXCLUDED
      MOLECULES” means molecules
      that have ******** as of the Effective Date, with the exception of ********,
      as
      identified in Schedule 2. 

    


    1.4  “FIELD
      OF
      USE” means
      uses of
      a product or ingredient other than those that would require,
      prior to the production or marketing of such product or ingredient, receipt
      of
      marketing approval from the U.S. Food and Drug Administration (or, with respect
      to activity outside the U.S., any substantially equivalent application from
      any
      applicable regulatory authority) pursuant to one of the following:

    


    (a)
      New
      Drug Application,

    (b)
      Biologics License Application,

    (c)
      Abbreviated New Drug Application,

    (d)
      Over-the-Counter (“OTC”) New Drug Application,

    (e)
      New
      Drug Application under Section 505(b)(2) of the U.S. Food, Drug and Cosmetic
      Act, and/or

    (f)
      OTC
      drug tentative final or final monograph,

    


    any
      of
      which (a)-(f) is effective, promulgated, and/or amended after the Effective
      Date. 

    


    Further,
      notwithstanding the foregoing, the use of EXCLUDED MOLECULES is specifically
      excluded from the FIELD OF USE hereunder.

     

    1.5 “FIRST
      COMMERCIAL SALE” means the first sale, rental, or lease of any LICENSED PRODUCT
      or first commercial use of a LICENSED PROCESS by LICENSEE, an AFFILIATE or
      a
      SUBLICENSEE, other than sale of a LICENSED PRODUCT or use of a LICENSED PROCESS
      for use in trials, such as field trials, being conducted to obtain governmental
      approvals to market LICENSED PRODUCTS or otherwise commercially use LICENSED
      PROCESSES. 

    


    1.6 “LICENSED
      PROCESS(ES)” means any process or method that, but for this Agreement, comprises
      an infringement (including contributory or inducement) of an issued, unexpired
      claim or a pending claim contained in the PATENT RIGHTS. 

    


    1.7 “LICENSED
      PRODUCT(S)” means any product that, but for this Agreement:

    


    (a)
      comprises an infringement (including contributory or inducement) of an issued,
      unexpired claim or a pending claim contained in the PATENT RIGHTS;
      or

    


    (b)
      is
      manufactured by using a LICENSED PROCESS.

    


    1.8 “NET
      SALES” means the gross revenue actually received by LICENSEE or AFFILIATES from
sale,
      rental
      or lease to a third party of LICENSED PRODUCTS and LICENSED PROCESSES covered
      by
      a VALID CLAIM of a PATENT RIGHT
      in the
      jurisdiction in which the sale, rental or lease occurs,
      less
      the following items (so
      long
      as such deductions are not obtained in view of other consideration received
      by
      LICENSEE:

    


    (a)
      cash
      discounts actually granted to customers in such invoices for sales or lease
      of
      LICENSED PRODUCTS, but only in amounts customary in the trade;

    


    (b)
      sales, tariff duties and/or use taxes separately stated in such bills or
      invoices with reference to particular sales and actually paid by LICENSEE or
      AFFILLIATES to a governmental unit;

    


    (c)
      actual freight expenses between LICENSEE or AFFILIATES and customers, to the
      extent such expenses are not charged to or reimbursed by customers;


    


    (d)
      amounts actually refunded or credited on returns; and

    


    (e)
      price
      allowances and trade discounts actually granted to customers.

    


    NET
      SALES
      shall exclude sales or transfers of LICENSED PRODUCTS and LICENSED PROCESSES
      between LICENSEE and an AFFILIATE, where the same are intended for resale to
      third parties. 

     

     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

     

    
      
         

      

      
        -1-

        
          

        

      

      
         

      

    

     

    Where
      LICENSEE or AFFILIATE receives any consideration other than cash for such
      transactions, fair market cash value for such consideration, to be agreed upon
      by the parties hereto, shall be included in NET SALES.

    


    1.9 “PATENT
      RIGHTS” means: 

    


    (a)
      the
      United States and foreign patents and/or patent applications, and divisionals,
      continuations, including
      continuations-in-part (but
      only
      to the extent that claims
      in
      such continuations-in-part
      are entitled to the priority date of
      another
      patent or application among
      the
      PATENT RIGHTS),
      and
      foreign counterparts of the same listed in Appendix A-1 and A-2; and 

    (b)
      United States and foreign patents issued from the applications listed in
      Appendix A-1
      and
      A-2,
      including any reissued or reexamined patents based upon the same.

    


    1.10 “ROYALTY
      PERIOD(S)” means the six-month periods ending on the last days of June and
      December each year.

    


    1.11 “SUBLICENSEE(S)”
      means any person or entity sublicensed, or granted an option for a sublicense,
      by LICENSEE under this Agreement, however, AFFILIATES and contract manufacturers
      are not SUBLICENSEES.

    


    1.12 “SUBLICENSE
      INCOME” means the amount actually received by LICENSEE from any and all
      SUBLICENSEES arising from the sublicense of the right to make, use, or sell
      LICENSED PRODUCTS or LICENSED PROCESSES. SUBLICENSE INCOME shall include
      up-front or license fees, milestone payments, royalties on sales, annual
      maintenance fees and any other direct payments in respect of the grant to such
      SUBLICENSEE of a sublicense of the right to make or sell LICENSED PRODUCTS
      or
      LICENSED PROCESSES, but only to the extent such amounts are directly
      attributable to the PATENT RIGHTS extended hereunder.

    


    1.13 “TERRITORY”
      means worldwide.

    


    1.14 “VALID
      CLAIM” means:

    


    (a)
      a
      claim within the PATENT RIGHTS that is in an issued patent and has not expired
      or been held invalid, revoked or unenforceable by a court or administrative
      agency of competent jurisdiction in a final and non-appealable
      judgment
      or in a
      judgment for which an appeal has not been filed within the time allowed for
      appeal, and which has not been disclaimed, denied or admitted to be invalid
      or
      unenforceable through reissue, reexamination or otherwise; or 

    


    (b)
      a
      claim that is in a patent application within
      the PATENT RIGHTS that has not yet issued and that is or will be under active
      prosecution and has been pending for less than four years.

     

    ARTICLE
      2 - GRANT OF LICENSE

    


    2.1 Subject
      to the terms and conditions of this Agreement and the sole non-exclusive license
      entered into prior to the Effective Date for the PATENT RIGHTS listed in
      APPENDIX A-2 (UM File #1442), MICHIGAN hereby grants to LICENSEE an
      exclusive license under PATENT RIGHTS with
      the
      right to grant sublicenses, both subject to the terms and conditions of this
      Agreement, in the FIELD OF USE and the TERRITORY to make, use, sell, offer
      for
      sale, import and otherwise exploit LICENSED PRODUCTS and LICENSED PROCESSES,
      and
      to have any of the foregoing done on its behalf. In
      the
      event MICHIGAN wishes to grant a license under the PATENT RIGHTS to any party
      for the EXCLUDED MOLECULES in the FIELD OF USE, MICHIGAN shall deliver a notice
      to LICENSEE stating MICHIGAN’s desire to grant a license, including a statement
      of the scope thereof. ********.

    


    2.2 MICHIGAN
      reserves the right to practice the PATENT RIGHTS for
      research, public service, internal (including clinical) and/or educational
      purposes,
      and the
      right to grant the same limited rights to other non-profit research
      institutions

    


    2.3 This
      Agreement shall extend until expiration of the last to expire of the licensed
      PATENT RIGHTS, unless sooner terminated as provided in another specific article
      of this Agreement.

    


    2.4 To
      the
      extent that the following grant may be required by research funding agreements
      between MICHIGAN and the United States Government, MICHIGAN reserves the right
      to grant to the United States Government nonexclusive, nontransferable,
      irrevocable, paid-up licenses to practice or have practiced for or on behalf
      of
      the United States PATENT RIGHTS throughout the world.

    


    2.5 LICENSEE
      is entitled to extend its licenses under this Article 2 to its AFFILIATES,
      consistent with all of the terms and conditions of this Agreement. If LICENSEE
      does extend its license and an AFFILIATE assumes obligations under the
      Agreement, LICENSEE guarantees performance by the AFFILIATE. If MICHIGAN has
      a
      claim arising under this Agreement against an AFFILIATE, MICHIGAN may seek
      a
      remedy directly against LICENSEE and may, but is not is not required to, seek
      a
      remedy against the AFFILIATE. Any termination of the Agreement under Article
      11
      as to LICENSEE also constitutes termination as to any AFFILIATES.

     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    


    
      
        
           

          


          
          

        

        
          -2-

          
            

          

        

        
          
          

          License
            Agreement between

          The
            University of Michigan and

          Quick-Med
            Technologies

          


        

      

    

    


     

    ARTICLE
      3 - CONSIDERATION

    


    3.1
       
      LICENSEE
      shall pay
      royalties to MICHIGAN until the expiration date of the last to expire of PATENT
      RIGHTS or until this Agreement is terminated. 
      Royalties shall include:

    


    (a)
      A
      License Issue Fee of ********Such License Issue Fee shall be nonrefundable
      and
      is due thirty days (30) from the complete execution of this
      Agreement; 

    


    (b)
      Royalties
      equal to ******** of NET SALES;

    


    (c)
      ********
      of
      SUBLICENSE INCOME;

    


    (d)
      LICENSEE shall pay to MICHIGAN an Annual License Maintenance Fee ("Annual Fee").
      This Annual Fee is accrued on June 30 of the years specified below, and is
      payable with the semi-annual report for the ROYALTY PERIOD in which the Annual
      Fee accrues. LICENSEE may credit each Annual Fee in full against all royalties
      otherwise due MICHIGAN for the prior July 1 through the June 30 on which the
      Annual Fee accrues. The annual license maintenance fees are:

    


    (1) In
      2008-2009: ********;

    


    (2) In
      2010:
      ********; and

    


    (3) In
      2011
      and in each year thereafter during the term of this Agreement: ********..


    


    Should
      this Agreement terminate or expire other than on a June 30, the Annual Fee
      for
      such portion of a year shall be determined by multiplying the amount set forth
      above for the given year by a fraction, the numerator of which shall be the
      number of days since the prior June 30 during which the Agreement is in effect
      and the denominator of which shall be three hundred and sixty-five.


    


    3.2 LICENSEE
      shall be responsible for the payment of all taxes, duties, levies, and other
      charges imposed by any taxing authority with respect to the royalties payable
      to
      MICHIGAN under this agreement. Should LICENSEE be required under any law or
      regulation of any government entity or authority to withhold or deduct any
      portion of the payments on royalties due to MICHIGAN, then the sum payable
      to
      MICHIGAN shall be increased by the amount necessary to yield to MICHIGAN an
      amount equal to the sum it would have received had no withholdings or deductions
      been made. MICHIGAN shall cooperate reasonably with LICENSEE in the event
      LICENSEE elects to assert, at its own expense, MICHIGAN’s exemption from any
      such tax or deduction.

    


    3.2 LICENSEE
      is not obligated to pay multiple royalties if any LICENSED PRODUCT or LICENSED
      PROCESS is covered by more than one claim of PATENT RIGHTS or the same LICENSED
      PRODUCT is covered by claims in two or more countries.

    


    3.3 If
      LICENSEE is obligated or reasonably deems it necessary to pay consideration
      to
      any third party that holds a patent(s) that would, in the reasonable judgment
      of
      LICENSEE be infringed by the manufacture, importation, use, offer for sale
      or
      sale of a LICENSED PRODUCT or a LICENSED PROCESS, LICENSEE may reduce the amount
      of royalties owed to MICHIGAN by an amount equal to fifty percent (50%) of
      the
      amount of royalties owed to such THIRD PARTY Licensor by LICENSEE. In no
      instance under this subsection may the royalty due to MICHIGAN be reduced below
      fifty percent (50%) of the amount that would have otherwise been owed by
      LICENSEE, however.

    


    3.4 If
      a
      LICENSED PRODUCT or LICENSED PROCESS is sold in a COMBINATION PRODUCT, then
      NET
      SALES for purposes of determining royalty payments on the COMBINATION PRODUCT
      or
      LICENSED PROCESS will be determined pro rata on a COMBINATION
      PRODUCT-by-COMBINATION PRODUCT and country-by-country basis until the date
      of
      expiration of the last to expire PATENT RIGHT covering the manufacture, use
      or
      sale of such COMBINATION PRODUCT in such country, calculated using one of the
      following methods:

    


    (a) By
      multiplying NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where
      A is the invoice price, during the royalty-paying period in question, of the
      LICENSED PRODUCT sold separately, and B is the invoice price during the royalty
      period in question, of the other products in the COMBINATION PRODUCT when sold
      separately by LICENSEE, its AFFILIATE or SUBLICENSEE or, if not so sold, then
      the average invoice price when sold separately by third parties; or

    


    (b) If
      no
      separate sales are made of the LICENSED PRODUCT or LICENSED PROCESS or any
      of
      the other products in such COMBINATION PRODUCT during the royalty-paying period
      in question, NET SALES for the purposes of determining royalty payments must
      be
      calculated by multiplying NET SALES of the COMBINATION PRODUCT by the fraction
      A/C, where A is as previously defined and C is the invoice price of the
      COMBINATION PRODUCT sold by LICENSEE, its AFFILIATE or SUBLICENSEE. If neither
      the royalty-bearing nor the non-royalty bearing product(s) included in the
      COMBINATION PRODUCT are sold separately, or the COMBINATION PRODUCT itself,
      or
      both, are not sold separately, NET SALES shall be calculated based on mutual
      written agreement as to a reasonable allocation between the LICENSED PRODUCT
      or
      LICENSED PROCESS and the other products in the COMBINATION PRODUCT, taking
      into
      account total manufacturing costs, proprietary protection and relative
      contribution of the products.

     

     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 


    
      
         

      

      
        -3-

        
          

        

      

      
         

      

    

    3.5 Royalty
      payments shall be paid to the "Regents of the University of Michigan" in United
      States dollars in Ann Arbor, Michigan, sent as provided in Article 13. In
      computing royalties, LICENSEE shall convert any revenues it receives in foreign
      currency into its equivalent in United States dollars at the most recent
      exchange rate published in the Wall Street Journal on the last business day
      of
      the ROYALTY PERIOD during which such payments are received by LICENSEE, or
      at
      such other exchange rate as the parties may agree to in writing.

    


    3.6 Royalty
      payments shall be made on a semi-annual basis with submission of the reports
      required by Article 4. All amounts due under this Agreement, including amounts
      due for the payment of patent expenses, shall, if overdue, be subject to a
      charge of interest compounded monthly until payment, at a per annum rate of
      five
      percent (5%) above the prime rate in effect at the JP Morgan Chase & Co. or
      its successor bank on the due date (or at the highest allowed rate if a lower
      rate is required by law) or $250, whichever is greater. The payment of such
      interest shall not foreclose MICHIGAN from exercising any other rights it may
      have resulting from any late payment. LICENSEE shall reimburse MICHIGAN for
      the
      costs, including reasonable attorney fees, for expenses paid in order to collect
      any amounts overdue more than 120 days.

    


    ARTICLE
      4 - REPORTS

    


    4.1 Until
      the
      FIRST COMMERCIAL SALE, LICENSEE shall provide to MICHIGAN a written annual
      report on or before October
      1
      of each
      year. The annual report shall include: reports of progress on research and
      development, regulatory approvals, manufacturing, sublicensing, marketing and
      sales during the preceding twelve (12) months, and plans for the coming year.
      LICENSEE also shall report to MICHIGAN the date of first sale or lease of
      LICENSED PRODUCTS (or results of LICENSED PROCESSES) in each country within
      thirty (30) days of occurrence.

    


    4.2 After
      the
      FIRST COMMERCIAL SALE, LICENSEE shall provide semi-annual reports to MICHIGAN.
      By each October
      1
      and April 1,
      LICENSEE
      shall report to MICHIGAN for that ROYALTY PERIOD: 

    


    (a)
      number of LICENSED PRODUCTS sold, leased or distributed by LICENSEE or
      AFFILIATE.

    (b)
      NET
      SALES, excluding the deductions provided therefor, of LICENSED PRODUCTS sold
      by
      LICENSEE or AFFILIATE.

    (c)
      accounting for all LICENSED PROCESSES used or sold by LICENSEE or AFFILIATE,
      including NET SALES, excluding the deductions therefor.

    (d)
      deductions applicable as provided in the definition for NET SALES
      above.

    (e)
      total
      SUBLICENSE INCOME and royalties due under Paragraph 3.1 above, including
      supporting figures.

    (f)
      foreign currency conversion rate and calculations (if applicable) and total
      royalties due.

    (g)
      names, addresses and U.S.P.T.O. Entity Status (as discussed in Paragraph 4.5)
      of
      all SUBLICENSEES having a sublicense or option therefor any time during the
      particular ROYALTY PERIOD.

    (h)
      for
      each sublicense or amendment thereto completed in the particular ROYALTY PERIOD,
      the date of each agreement and amendment, the territory of the sublicense,
      the
      scope of the sublicense, and the nature, timing and amounts of all fees and
      royalties to be paid thereunder.

    (i)
      any
      milestone (under Article 5) that has been achieved, and any milestone that
      was
      due during the ROYALTY PERIOD but not achieved, specifying each milestone and
      whether or not it was achieved.

    


    LICENSEE
      shall include the amount of all payments due, and the various calculations
      used
      to arrive at those amounts, including the quantity, description (nomenclature
      and type designation as described in Paragraph 4.3 below), country of
      manufacture and country of sale of LICENSED PRODUCTS and LICENSED PROCESSES.
      LICENSEE shall direct its authorized representative to certify that reports
      required hereunder are correct to the best of LICENSEE's knowledge and
      information. Failure to provide reports as required under this Article 4 shall
      be considered
      a
      material breach of this Agreement.

    


    If
      no
      payment is due, LICENSEE shall so report to MICHIGAN that no payment is
      due.

    


    4.3 LICENSEE
      shall promptly establish and consistently employ a system of specific
      nomenclature and type designations for LICENSED PRODUCTS and LICENSED PROCESSES
      to permit identification and segregation of various types where necessary.
      LICENSEE shall consistently employ, and shall require SUBLICENSEES to
      consistently employ, the system when rendering invoices thereon and shall inform
      MICHIGAN, or its auditors, when requested, as to the details concerning such
      nomenclature system, all additions thereto and changes therein.

     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    
      
         

      

      
        -4-

        
          

        

      

      
         

      

    

     

    4.4 LICENSEE
      shall keep, and shall require AFFILIATES and SUBLICENSEES to keep, true and
      accurate records containing data reasonably required for the computation and
      verification of payments due under this Agreement. LICENSEE shall, and it shall
      require all AFFILIATES and SUBLICENSEES to: (a) open such records for inspection
      upon reasonable notice during business hours by either MICHIGAN auditor(s)
      or an
      independent certified accountant selected by MICHIGAN, for the purpose of
      verifying the amount of payments due; and (b) retain such records for six (6)
      years from date of origination. 

    


    The
      terms
      of this Article shall survive any termination of this Agreement. MICHIGAN is
      responsible for all expenses of such inspection, except that if any inspection
      reveals an underpayment greater than five percent (5%) of royalties due
      MICHIGAN, then LICENSEE shall pay all expenses of that inspection and the amount
      of the underpayment and interest to MICHIGAN within twenty-one (21) days of
      written notice thereof. LICENSEE shall also reimburse MICHIGAN for reasonable
      expenses required to collect the amount underpaid.

    


    4.5 So
      that
      MICHIGAN may pay the proper U.S. Patent and Trademark Office fees relating
      to
      the PATENT RIGHTS, if LICENSEE, any company related to LICENSEE or SUBLICENSEE
      (including optionees) does not qualify as a “Small Entity” under U.S. patent
      laws, LICENSEE shall notify MICHIGAN immediately. The parties understand that
      the changes to LICENSEE’s, SUBLICENSEE’s, or optionees’ businesses that might
      affect entity status include: acquisitions, mergers, hiring of a total of more
      than 500 total employees, sublicense agreements, and sublicense options.


    
 

    ARTICLE
      5 - DILIGENCE

    


    5.1 
      LICENSEE
      shall use commercially reasonable efforts to bring LICENSED PRODUCTS to market
      or one or more LICENSED PROCESSES to commercial use. LICENSEE has the
      responsibility to do all that is necessary to obtain and retain any governmental
      approvals to manufacture and/or sell LICENSED PRODUCTS and/or use LICENSED
      PROCESSES for all relevant activities of LICENSEE, AFFILIATES and
      SUBLICENSEES.

    


    5.2 As
      part
      of the diligence required by Paragraph 5.1, LICENSEE agrees to reach the
      following commercialization and research and development milestones for the
      LICENSED PRODUCTS and LICENSED PROCESSES (together the “MILESTONES”) by the
      following dates: 

    


    1)
      Initiate
      communication
      with all
      Tier 1 (Largest
      - see Schedule 2) Cosmetic or Chemical Companies with Category 1 Products
      (defined at those which explicitly use ******** within their product or
      marketing literature during ********.

    


    2)
      Initiate communication with all Tier 2 Companies (Significant size, but not
      the
      very largest - see Schedule 3) with Category 1 products during
      ********.

    


    3)
      Complete product research on all Category 2 (defined as those products which
      are
      suspected by LICENSEE of using ******** by virtue of claimed activity or
      description of active ingredients) within ********. 

    4)
      Initiate communication
      with all
      Tier 1 Companies with Category 2 products (to be determined based on research
      completed in Milestone #3) within
      ********.

    


    5)
      Within
      ******** of the effective date of this agreement, LICENSEE will obtain at least
      **** new revenue-generating business relationship from among the Companies
      currently or prospectively identified as Tier 1 or 2 Companies. Additional
      royalties to MICHIGAN from such additional business under Section 3.1 (b) or
      (c)
      herein shall be at least ******** per year. In the event that such business
      relationships do not generate at least ***** per year in additional royalties,
      the Annual Fee due MICHIGAN (as defined in Section
      3.1
      (d)) shall be increased by the difference between ****** and the royalty amount
      actually incurred. 

    


    5.3 LICENSEE
      must achieve the MILESTONES on or before the deadline dates indicated. LICENSEE
      shall notify MICHIGAN within ten (10) days after each deadline as to whether
      such MILESTONE was met. If LICENSEE fails to meet any MILESTONE under this
      Article continues for forty-five (45) days after the date of any MILESTONE
      deadline, LICENSEE will be deemed to be in material breach of this Agreement,
      and MICHIGAN may terminate the Agreement as provided in section 11.3.


    


    


    ARTICLE
      6 - SUBLICENSING

    


    6.1 LICENSEE
      shall notify MICHIGAN in writing of every sublicense agreement and each
      amendment thereto within thirty (30) days after their execution, and indicate
      the name of the SUBLICENSEE and its number of employees, the territory of the
      sublicense, the scope of the sublicense, and the nature, timing and amounts
      of
      all fees and royalties to be paid thereunder. Upon request, LICENSEE shall
      provide MICHIGAN with a copy of sublicense agreements.

     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 


    
      
         

      

      
        -5-

        
          

        

      

      
         

      

    

    6.2 Where
      LICENSEE receives any consideration other than cash from SUBLICENSEES,
SUBLICENSE
      INCOME for said consideration shall be the
      fair
      market cash value for such consideration.

    


    6.3 Each
      sublicense granted by LICENSEE under this Agreement shall provide for its
      termination upon termination of this Agreement. Each sublicense shall terminate
      upon termination of this Agreement unless LICENSEE has previously assigned
      its
      rights under the sublicense to MICHIGAN and MICHIGAN has agreed at its sole
      discretion in writing to such assignment.

    


    
      	
              6.4

            	
              LICENSEE
                shall require that all sublicenses:

            


    

    


    (1)
      be
      consistent with the terms and conditions of this Agreement;

    


    (2)
      contain the SUBLICENSEE'S acknowledgment of the disclaimer of warranty and
      limitation on MICHIGAN's liability, as provided by Article 9 below; and


    


    (3)
      contain provisions under which the SUBLICENSEE accepts duties at least
      equivalent to those accepted by the LICENSEE in the following Paragraphs: 4.4
      (duty to keep records); 4.5 (duty regarding Patent Office fees); 9.4 (duty
      to
      avoid improper representations or responsibilities); 10.1 (duty to defend,
      hold
      harmless, and indemnify MICHIGAN); 10.3 (duty to maintain insurance); 14.5
      (duty
      to properly mark LICENSED PRODUCTS with patent notices); 14.7 (duty to restrict
      the use of MICHIGAN's name); 14.8 (duty to control exports).

    


    


    ARTICLE
      7 - PATENT APPLICATIONS AND MAINTENANCE 

    


    7.1 MICHIGAN
      has the right to control filing, prosecuting, and maintaining all of the patents
      and patent applications
      that form the basis for the PATENT RIGHTS, including
      interferences
      and
      disputes regarding
      inventorship
      (including litigation based solely or primarily upon inventorship
      issued),
      with
      reasonable input from LICENSEE. LICENSEE shall fully cooperate in such
      activities.

    


    7.2 MICHIGAN
      shall notify LICENSEE of all information received by MICHIGAN relating to the
      filing, prosecution and maintenance of the patents and patent applications
      which
      form the basis of the PATENT RIGHTS, and shall provide LICENSEE reasonable
      time
      to review, comment, and advise upon such information. MICHIGAN agrees to act
      on
      recommendations of LICENSEE when it is reasonable to do
      so.
      LICENSEE
      agrees to hold such information confidential and to use the information provided
      by MICHIGAN only for the purpose of advancing MICHIGAN’s PATENT
      RIGHTS.
      MICHIGAN
      agrees that claims contained in a continuation-in-part application that are
      not
      entitled to the priority date of a patent among the PATENT RIGHTS will be
      segregated to the extent permitted by law into a separate patent at LICENSEE’S
      request and that LICENSEE shall have no financial obligation to MICHIGAN for
      such separate patent applications, although such rights shall not be included
      in
      PATENT RIGHTS. 

    


    7.3 LICENSEE
      shall reimburse MICHIGAN for fifty percent (50%) of all fees and costs
incurred
      after the Effective Date of this Agreement relating
      to the activities described in this Article and
      shall
      reimburse MICHIGAN for 
      costs
      already incurred according to the following schedule: Forty thousand dollars
      ($40,000) within ten days of the Effective Date, thirteen thousand dollars
      ($13,000) no later than December 31, 2007, thirteen thousand dollars ($13,000)
      no later than December 31, 2008 and thirteen thousand dollars ($13,000) no
      later
      than December 31, 2009. MICHIGAN shall provide LICENSEE with copies of original
      invoices setting forth such costs in detail for all costs incurred after the
      Effective Date of this Agreement.
      Such
      reimbursement shall be made within thirty (30) days of receipt of MICHIGAN’s
      invoice and shall be subject to the interest and other requirements specified
      in
      Paragraph 3.6 above. LICENSEE
      may, at its option and sixty (60) days prior to any outstanding action, elect
      to
      relinquish its license under any patent or application among the PATENT RIGHTS,
      in which case LICENSEE’s reimubursement obligations under this Article with
      respect to that patent or patent application shall cease.

    
********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    
      
         

      

      
        -6-

        
          

        

      

      
         

      

    

    ARTICLE
      8 - ENFORCEMENT

    


    8.1 Each
      party shall promptly advise the other in writing of any known acts of potential
      infringement of the PATENT RIGHTS by another party in the FIELD OF USE. LICENSEE
      has the first option to police the PATENT RIGHTS against infringement by other
      parties within the TERRITORY and the FIELD OF USE, but LICENSEE shall notify
      MICHIGAN in writing thirty (30) days before filing any suit. LICENSEE shall
      not
      file any suit without a diligent investigation of the merits of such suit by
      counsel, including with respect to PATENT RIGHTS. This right to police includes
      defending any action for declaratory judgment of noninfringement or invalidity;
      and prosecuting, defending or settling all infringement and declaratory judgment
      actions at its expense and through counsel of its selection, except that
      LICENSEE shall make any such settlement only with the advice and consent of
      MICHIGAN. If LICENSEE has a reasonable basis for policing the patents, MICHIGAN
      shall provide reasonable assistance to LICENSEE with respect to such actions,
      but only if LICENSEE reimburses MICHIGAN for out-of-pocket expenses incurred
      in
      connection with any such assistance rendered at LICENSEE'S request or reasonably
      required by MICHIGAN and if LICENSEE notifies MICHIGAN in writing fourteen
      (14)
      days
      before filing any suit,
      unless
      MICHIGAN waives such notice requirement in writing.
      MICHIGAN
      retains the right to participate, with counsel of its own choosing and at its
      own expense, in any action under this Paragraph. LICENSEE shall defend,
      indemnify and hold harmless MICHIGAN with respect to any counterclaims asserted
      by an alleged infringer reasonably related to the enforcement of the PATENT
      RIGHTS under this Paragraph, including but not limited to antitrust
      counterclaims and claims for recovery of attorney fees. 

    


    If
      a
      declaratory judgment action alleging invalidity or unenforceability of any
      of
      the PATENT RIGHTS is brought against LICENSEE or MICHIGAN and the action is
      not
      brought in reaction to an assertion of or action for patent infringement brought
      by LICENSEE, then MICHIGAN, at its sole option, has the right to intervene
      and
      assume control over the defense of such action, and LICENSEE shall provide
      reasonable cooperation in the defense of such action. If a third party files
      such action as the result of acts of LICENSEE, then LICENSEE shall reimburse
      the
      reasonable costs and fees of MICHIGAN in defending such action. 

    


    8.2 
      If
      LICENSEE demonstrates to MICHIGAN that it has a reasonable basis to believe
      that
      a third party infringes the PATENT RIGHTS and undertakes to enforce and/or
      defend the PATENT RIGHTS by litigation anywhere
      in
      the
world,
      LICENSEE may withhold
      up to fifty percent (50%) of the payments otherwise thereafter due
      in the
      jurisdiction in which said PATENT RIGHTS are being enforced
      during
      the course of such litigation to MICHIGAN under Article 3 under the following
      terms. LICENSEE may apply the amounts withheld to pay up to half of LICENSEE's
      out-of-pocket litigation expenses, including reasonable attorneys’ fees, but not
      including salaries of LICENSEE’s employees. If LICENSEE recovers damages in
      patent litigation or settlement thereof, the award shall be applied first to
      satisfy LICENSEE’S unreimbursed expenses and legal fees for the litigation, next
      to reimburse MICHIGAN for any payments under Article
      3
      which are past due or were withheld pursuant to this Article 8, and then to
      reimburse MICHIGAN for any other reasonable unreimbursed expenses and legal
      fees
      for the litigation. The
      remaining balance shall be divided with 80% received by LICENSEE and 20%
      received by MICHIGAN. This provision shall control the division of revenues
      where a license is granted as part of a settlement of such litigation.


    


    8.3 If
      LICENSEE fails to take action to abate any alleged infringement of patents
      which
      form the basis for the PATENT RIGHTS within one-hundred-and-eighty (180) days
      of
      a request by MICHIGAN to do so (or within a shorter period if required to
      preserve the legal rights of MICHIGAN under any applicable laws) then MICHIGAN
      has the right to take such action (including prosecution of a suit) at its
      expense and LICENSEE shall use reasonable efforts to cooperate in such action,
      at LICENSEE's expense. Such abatement may include compensating MICHIGAN for
      some
      part of any alleged damages, as negotiated by the Parties. MICHIGAN has full
      authority to settle on such terms as MICHIGAN determines, except that MICHIGAN
      shall not reach any settlement whereby it provides a license for future
      activities to a third party under the PATENT RIGHTS in the TERRITORY and the
      FIELD OF USE without the consent of LICENSEE. If MICHIGAN recovers damages
      in
      patent litigation or settlement thereof, the award shall be applied first to
      satisfy MICHIGAN’S unreimbursed expenses and legal fees for the litigation, next
      to reimburse MICHIGAN for any payments overdue under this Agreement, and then
      to
      reimburse LICENSEE for any reasonable unreimbursed expenses and legal fees
      for
      the litigation (such payment not to exceed the recovery or settlement amounts
      MICHIGAN actually receives). The remaining balance shall be divided with 80%
      received by MICHIGAN and 20% by LICENSEE. This
      provision shall control the division of revenues where a license is granted
      as
      part of a settlement of such litigation.

     

    
      ******** This
        material has been omitted pursuant to a request for confidential treatment
        and
        filed separately with the Securities and Exchange Commission. 

      
        -7-

        
          

        

      

      
         

      

    

    ARTICLE
      9 - NO WARRANTIES; LIMITATION ON MICHIGAN'S LIABILITY

    


    9.1 MICHIGAN,
      including its Regents, fellows, officers, employees and agents, makes no
      representations or warranties that PATENT RIGHTS are or will be held valid,
      or
      that the manufacture, importation, use, offer for sale, sale or other
      distribution of any LICENSED PRODUCTS or use of LICENSED PROCESSES will not
      infringe upon any patent or other rights.

    


    9.2 MICHIGAN,
      INCLUDING ITS REGENTS, FELLOWS, OFFICERS, EMPLOYEES AND AGENTS, MAKES NO
      REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
      INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY OR
      FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER
      WITH
      RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION
      BY
LICENSEE
      OR
      SUBLICENSEES
      OF
LICENSED
      PRODUCTS OR
      LICENSED PROCESSES.

    


    9.3 LICENSEE
      AND
SUBLICENSEES
      ASSUME
      THE ENTIRE RISK AS TO PERFORMANCE OF LICENSED
      PRODUCTS AND
      LICENSED PROCESSES.
      In no
      event shall MICHIGAN, including its Regents, fellows, officers, employees and
      agents, be responsible or liable for any direct, indirect, special, incidental,
      or consequential damages or lost profits or other economic loss or damage with
      respect to LICENSED PRODUCTS or LICENSED PROCESSES, to LICENSEE, SUBLICENSEES
      or
      any other individual or entity regardless of legal or equitable theory. The
      above limitations on liability apply even though MICHIGAN, its Regents, fellows,
      officers, employees or agents may have been advised of the possibility of such
      damage.

    


    9.4 LICENSEE
      shall not, and shall require that its SUBLICENSEES do not, make any statements,
      representations or warranties whatsoever to any person or entity, or accept
      any
      liabilities or responsibilities whatsoever from any person or entity that are
      inconsistent with any disclaimer or limitation included in this Article
      9.

    


    


    ARTICLE
      10 - INDEMNITY; INSURANCE

    


    10.1 LICENSEE
      shall defend, indemnify and hold harmless and shall require SUBLICENSEES to
      defend, indemnify and hold harmless MICHIGAN, including its Regents, fellows,
      officers, employees, students, and agents, for and against any and all claims,
      demands, damages, losses, and expenses of any nature (including attorneys'
      fees
      and other litigation expenses), resulting from, but not limited to, death,
      personal injury, illness, property damage, economic loss or products liability
      arising from or in connection with, any of the following: (1) Any manufacture,
      use, sale or other disposition by LICENSEE, SUBLICENSEES or transferees of
      LICENSED PRODUCTS or LICENSED PROCESSES and
      (2) The
      direct or indirect use by any person of LICENSED PRODUCTS made, used, sold
      or
      otherwise distributed by LICENSEE or SUBLICENSEES 

    


    10.2 MICHIGAN
      is entitled to participate at its option and expense through counsel of its
      own
      selection, and may join in any legal actions related to any such claims,
      demands, damages, losses and expenses under Paragraph 10.1 above. LICENSEE
      shall
      not settle any such legal action with an admission of liability of MICHIGAN
      without MICHIGAN’s written approval.

    


    10.3 Prior
      to
      any distribution or commercial use of any LICENSED PRODUCT or use of any
      LICENSED PROCESS by LICENSEE, LICENSEE shall purchase and maintain in effect
      commercial general liability insurance, including product liability insurance
      and errors and omissions insurance which shall protect LICENSEE and MICHIGAN
      with respect the events covered by Paragraph 10.1. Prior to any distribution
      or
      use of any LICENSED PRODUCT or use of any LICENSED PROCESS by a SUBLICENSEE,
      LICENSEE shall require that the SUBLICENSEE purchase and maintain in effect
      commercial general liability insurance, including product liability insurance
      and errors and omissions insurance which shall protect LICENSEE, SUBLICENSEE,
      and MICHIGAN with respect to the events covered by Paragraph 10.1. Each such
      insurance policy must provide reasonable coverage for all claims with respect
      to
      any LICENSED PROCESS used and any LICENSED PRODUCTS manufactured, used, sold,
      licensed or otherwise distributed by LICENSEE -- or, in the case of a
      SUBLICENSEE's policy, by said SUBLICENSEE -- and must specify MICHIGAN,
      including its Regents, fellows, officers and employees, as an additional
      insured. LICENSEE shall furnish certificate(s) of such insurance to MICHIGAN,
      upon request.

    


    10.4 In
      no
      event shall either party hereunder be liable to the other for any special,
      indirect, or consequential damages of any kind whatsoever resulting from any
      breach or default of this Agreement.

     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    
      
         

      

      
        -8-

        
          

        

      

      
         

      

    

    ARTICLE
      11 - TERM AND TERMINATION 

    


    11.1 If
      LICENSEE ceases to carry on its business, this Agreement shall terminate upon
      written notice by MICHIGAN attempted to be delivered to the address for notices
      provided in Article 13.

    


    11.2 Failure
      by
      LICENSEE
      to (a)
      make any Annual License Maintenance Fee due to MICHIGAN, under Section 3.1
      (d)
      or (b) submit any report under Article 4 shall
      be
      considered a material breach of this
      Agreement. If LICENSEE fails to cure such breach within thirty (30) days of
      receiving written notice of said breach by MICHIGAN, MICHIGAN
      may terminate the Agreement. LICENSEE shall be entitled to a thirty (30)
      business day extension of such period if it represents to MICHIGAN in writing
      the failure to provide any such report was due to a good faith error or
      circumstances beyond LICENSEE’s control. Such
      termination shall not foreclose MICHIGAN from collection of any amounts
      remaining unpaid or seeking other legal relief.

    


    11.3 Other
      than as provided for in Sections 11.1 and 11.2 above, in the event of any
      dispute arising from or relating to this Agreement or the breach thereof, the
      parties hereto shall use diligent efforts to settle the dispute. MICHIGAN shall
      not terminate the Agreement for breach until a dispute resolution process,
      as
      follows, is complete and LICENSEE is adjudicated to be in material breach of
      the
      Agreement. 

    


    Dispute
      Resolution Process:

    


    
      	(a)  	
              Negotiation:
                Senior individuals with responsibility for patent and licensing activities
                of the disputing Parties, with advice of counsel if necessary, shall
                consult and negotiate with each other in good faith and, recognizing
                their
                mutual interests, attempt to reach a just and equitable solution
                satisfactory to both parties. The parties shall diligently attempt
                to
                resolve such issue amicably with a sufficiently authorized member
                of each
                Party's management over a period of 60 days after request by either
                Party,
                which attempt shall include at least one in-person meeting of the
                parties
                involved in the discussions in Washtenaw County,
                Michigan.

            


    

    


    
      	(b)  	
              Mediation:
                 If
                such dispute or controversy cannot be settled through the above
                activities, the Parties agree to attempt in good faith to settle
                the
                controversy with mediation which shall be completed 45 days after
                completion of the negotiation period provided for in Section 11.3(a).
                The
                Parties shall equally share the fees and the costs of a mutually
                agreeable
                mediator, with each Party also being responsible for its own expenses.
                The
                Parties shall agree upon the terms of such mediation, which shall
                include
                at least one in-person meeting in Washtenaw County, Michigan, involving
                senior individuals with responsibility for patent and licensing activities
                of the disputing Parties, such meeting taking place at least 21 days
                prior
                to the completion of the mediation.


            


    

    


    
      	(c)  	
              If
                the parties do not reach such solution through formal mediation,
                then,
                upon written notice by one Party to the other Party, disputes shall
                be
                finally settled by binding
                arbitration.

            


    

    


    
      	(1)  	
              The
                arbitration shall be administered by the American Arbitration Association
                in accordance with the provisions of its Commercial Arbitration rules,
                and/or its Patent Arbitration rules, whichever is reasonably applicable,
                and Federal Arbitration Act, except where those rules conflict with
                this
                provision, in which case this provision controls. The written notice
                must
                contain a statement of the dispute in sufficiently clear detail for
                the
                arbitrators and the other party to understand it. Prior to commencement
                of
                arbitration, emergency relief is available from any court only to
                avoid
                irreparable harm.

            


    

    


    
      	(2)  	
              The
                arbitration shall take place before a single arbitrator in Washtenaw
                County, Michigan USA, unless in-person meetings or hearing are not
                necessary or required. Unless the Parties agree otherwise, the Parties
                shall agree upon the arbitrator within twenty business days from
                the date
                of the written notice referenced in Section 11.3 (c) above from the
                AAA’s
                National Roster of Arbitrators or through selection procedures
                administered by the AAA. The arbitrator shall not be employed by
                or
                affiliated in any way with either Party (including, for example,
                as an
                independent consultant or as a customer or vendor to either party,
                or an
                employee of a customer or vendor). LICENSEE shall pay the fees and
                the
                costs of the arbitrator, with each Party also being responsible for
                its
                own expenses.

            


    

    


    
      	(3)  	
              Within
                15 business days after the selection of the arbitrator, the parties
                shall
                reach agreement upon and thereafter follow procedures, including
                limits on
                discovery, assuring
                that the arbitration will be concluded and the award rendered within
                no
                more than six (6) months from selection of the arbitrator(s). In
                the
                absence of an agreement to the contrary or except as provided herein,
                procedures meeting such time limits will be designed by the AAA and
                adhered to by the parties. 

            


    

    


    
      	(4)  	
              The
                Federal Rules of Civil Procedure shall apply where the rules of the
                American Arbitration Association are silent, but the parties shall
                use
                their best efforts to come to agreement on limits on discovery. To
                the
                extent that depositions are permitted, unless the parties agree to
                further
                limits, each deposition of a person shall be limited to 6 hours of
                testimony, and depositions of parties shall
                be
                limited to 10 hours of testimony and each party shall be limited
                to 5
                depositions. Unresolved discovery disputes shall be resolved by the
                arbitrator(s).

            


    

    


    
      	(5)  	
              The
                decision of the arbitrator(s) must be in writing and must generally
                describe the basis on which the decision was made, but a detailed
                written
                opinion shall not be required of the arbitrator(s). Judgment on the
                award
                rendered by the arbitrator(s) may be entered in any court having
                competent
                jurisdiction thereof. Each party shall bear its own costs and expenses
                and
                an equal share of the arbitrator and administrative fees of the
                arbitration. THE ARBITRATOR(S) SHALL NOT AWARD EITHER PARTY PUNITIVE,
                EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL DAMAGES, OR ATTORNEYS FEES
                OR
                COSTS.

            


    

    


    
      	(6)  	
              This
                agreement to arbitrate is intended to be binding upon the signatories
                hereto, their principals, successors, assigns, subsidiaries, and
                affiliates. This agreement to arbitrate is also intended to include
                any
                disputes, controversy or claims against any party's employees, agents,
                representatives, or outside legal counsel arising out of or relating
                to
                matters covered by this Agreement or any agreement in which this
                Agreement
                is incorporated.

            


    

    


    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    
      
         

      

      
        -9-

        
          

        

      

      
         

      

    

    
 

    11.4 LICENSEE
      has the right to terminate this Agreement at any time on ninety (90) days’
written notice to MICHIGAN if LICENSEE:

    


    (a)
      pays
      all amounts due MICHIGAN through the effective date of the
      termination;

    


    (b)
      submits a final report of the type described in Paragraph 4.2;

    


    (c)
      returns any patent documentation (including that exchanged under Article 7)
      and
      any other confidential or trade-secret materials provided to LICENSEE by
      MICHIGAN in connection with this Agreement, or, with prior approval by MICHIGAN,
      destroys such materials, and certifies in writing that such materials have
      all
      been returned or destroyed; and

    


    (d)
      suspends its manufacture, use and sale of the LICENSED PROCESS(ES) AND LICENSED
      PRODUCT(S) (subject to Paragraphs
      11.5
and
      11.7
      below).

     

    Upon
      written
      notice
      of intent to terminate, MICHIGAN may elect
      to
      immediately terminate this Agreement upon written notice. The
      effective date of such termination shall be the earlier of: (a) the date
indicated
      by
      LICENSEE
in
      its
      written
      notice of termination, and (b) the date on which MICHIGAN provides LICENSEE
      with
      written notice
      of
      immediate termination. During the period between notice and termination MICHIGAN
      shall not initiate any new litigation or prosecution under the PATENT RIGHTS
      or
      otherwise obligate LICENSEE by incurring expenses which need not necessarily
      be
      incurred before the date
      of
      termination. However, nothing in this Paragraph shall limit LICENSEE’s
      obligations under Article 7 with respect to: (a) patent applications filed
      as of
      the date of such notice and/or (b) fees due during the notice period that were
      foreseeable at the time of such notice, including but not limited to patent
      maintenance fees. 

    


    11.5 Upon
      any
      termination of this Agreement, and except as provided herein to the contrary,
      all rights and obligations of the parties hereunder shall cease, except any
      previously accrued rights and obligations and further as follows:

    


    (1)
      obligations to pay (this
      needs to stay in) consideration
      accruing
      hereunder up to the day of such termination, whether or not this Agreement
      provides for a number of days before which actual payment is due and such date
      is after the day of termination; 

    


    (2)
      MICHIGAN's rights to inspect books and records as described in Article 4, and
      LICENSEE's obligations to keep such records for the required time; 

    


    (3)
      any
      cause of action or claim of LICENSEE or MICHIGAN accrued or to accrue because
      of
      any breach or default by the other party hereunder; 

    


    (4)
      the
      provisions of Articles 1, 9, 10, and 14.

    


    11.6 
      After
      the license(s) granted herein terminate, if LICENSEE has filed patent
      applications or obtained patents to any modification or improvement to LICENSED
      PRODUCTS or LICENSED PROCESSES within the scope of the PATENT RIGHTS, LICENSEE
      agrees upon request to enter into good faith negotiations with MICHIGAN or
      MICHIGAN’s future licensee (s) for
      the
      purpose of granting licensing rights to said modifications or improvements
      in a
      timely fashion and under commercially reasonable terms.

    


    11.7 After
      the
      license(s) granted herein terminate, LICENSEE shall have the right to sell
      or
      otherwise dispose of any inventory of LICENSED PRODUCTS, and shall pay MICHIGAN
      any royalties due thereon pursuant to the provisions of Article 3 herein.


     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    
      
         

      

      
        -10-

        
          

        

      

      
         

      

    

     

    ARTICLE
      12 - REGISTRATION AND RECORDATION

    


    12.1 If
      the
      terms of this Agreement, or any assignment or license under this Agreement
      are
      or become such as to require that the Agreement or license or any part thereof
      be registered with or reported to a national or supranational agency, LICENSEE
      will, at its expense, undertake such registration or report. Prompt notice
      and
      appropriate verification of the act of registration or report or any agency
      ruling resulting from it will be supplied by LICENSEE to MICHIGAN upon
      request.

    


    12.2 LICENSEE
      shall also carry out, at its expense, any formal recordation of this Agreement
      or any license herein granted that the law of any country requires as a
      prerequisite to enforceability of the Agreement or license in the courts of
      any
      such country or for other reasons, and shall promptly furnish to MICHIGAN
      appropriately verified proof of recordation.

    


    


    ARTICLE
      13 - NOTICES

    


    13.1 Any
      notice, request, report or payment required or permitted to be given or made
      under this Agreement by either party is effective when mailed if sent by
      recognized overnight carrier or certified mail, electronic mail followed by
      confirmation by regular U.S. mail, or registered mail (return receipt requested)
      to the address set forth below or such other address as such party specifies
      by
      written notice given in conformity herewith. Any notice, request, report or
      payment not so given is not effective until actually received by the other
      party. 

    


     

    To
      MICHIGAN:     To
      LICENSEE:

    


    The
      University of Michigan    Quick-Med
      Technologies, Inc 

    Office
      of
      Technology Transfer  3427
      SW
      42nd
      Way


    Wolverine
      Tower, Room 2071  Gainesville,
      Florida 32608

    3003
      S.
      State Street    

    Ann
      Arbor, MI 48109-1280   

    


    Attn:
      File No. 1175, 1356, 1442,  
      Attn: Michael
      Granito

    1442d1,
      1442d3, 1543, 1543d1, 

    1720,
      2044 and 2115

    


    


    ARTICLE
      14 - MISCELLANEOUS PROVISIONS

    


    14.1
       This
      Agreement shall be construed, governed, interpreted and applied according to
      United States and State of Michigan law, except that questions affecting the
      construction and effect of any patent shall be determined by the law of the
      country in which the patent was granted.

    


    14.2 The
      parties hereby consent to the jurisdiction of the courts in the State of
      Michigan over any dispute concerning this Agreement or the relationship between
      the parties. Should LICENSEE bring any claim, demand or other action against
      MICHIGAN, its Regents, fellows, officers, employees or agents, arising out
      of
      this Agreement or the relationship between the parties, LICENSEE agrees to
      bring
      said action only in the Michigan Court of Claims.

     

    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    
      
         

      

      
        -11-

        
          

        

      

      
         

      

    

    14.3 MICHIGAN
      and LICENSEE agree that this Agreement sets forth their entire understanding
      concerning the subject matter of this Agreement. The parties may amend this
      Agreement from time to time, but no modification will be effective unless both
      MICHIGAN and LICENSEE agree to it in writing.

    


    14.4
       If
      a
      court of competent jurisdiction finds any term of this Agreement invalid,
      illegal or unenforceable, that term will be curtailed, limited or deleted,
      but
      only to the extent necessary to remove the invalidity, illegality or
      unenforceability, and without in any way affecting or impairing the remaining
      terms.

    


    14.5 LICENSEE
      agrees to mark the LICENSED PRODUCTS sold in the United States with all
      applicable United States patent numbers. All LICENSED PRODUCTS shipped to or
      sold in other countries shall be marked to comply with the patent laws and
      practices of the countries of manufacture, use and sale.

    


    14.6 No
      waiver
      by either party of any breach of this Agreement, no matter how long continuing
      or how often repeated, is a waiver of any subsequent breach thereof, nor is
      any
      delay or omission on the part of either party to exercise or insist on any
      right, power, or privilege hereunder a waiver of such right, power or
      privilege.

    


    14.7 LICENSEE
      agrees to refrain from using and to require SUBLICENSEES to refrain from using
      the name of MICHIGAN in publicity or advertising without the prior written
      approval of MICHIGAN. Reports in scientific literature and presentations of
      joint research and development work are not publicity. Notwithstanding this
      provision, without prior written approval of MICHIGAN, LICENSEE and SUBLICENSEES
      may state publicly that LICENSED PRODUCTS and PROCESSES were developed by
      LICENSEE based upon an invention(s) developed at the University of Michigan
      and/or that the PATENT RIGHTS were licensed from the University of Michigan.
      

    


    14.8 LICENSEE
      agrees to comply with all applicable laws and regulations. In particular,
      LICENSEE understands and acknowledges that the transfer of certain commodities
      and technical data is subject to United States laws and regulations controlling
      the export of such commodities and technical data, including all Export
      Administration Regulations of the United States Department of Commerce. These
      laws and regulations prohibit or require a license for the export of certain
      types of technical data to certain specified countries. LICENSEE agrees to
      comply with all United States laws and regulations controlling the export of
      commodities and technical data, to be solely responsible for any violation
      of
      such laws and regulations by LICENSEE or its SUBLICENSEES, and to defend,
      indemnify and hold harmless MICHIGAN and its Regents, fellows, officers,
      employees and agents if any legal action of any nature results from the
      violation.

    


    14.9 The
      relationship between the parties is that of independent contractor and
      contractee. Neither party is an agent of the other in connection with the
      exercise of any rights hereunder, and neither has any right or authority to
      assume or create any obligation or responsibility on behalf of the
      other.

    


    14.10 LICENSEE
      may, without MICHIGAN’s consent, assign its rights under this Agreement to a
      purchaser of all or substantially all of LICENSEE’s business relating to the
      subject matter of this Agreement, so long as such assignee provides a statement
      in writing to MICHIGAN that it agrees to accept all the terms and conditions
      of
      this Agreement in the place of LICENSEE. LICENSEE may not assign this Agreement
      otherwise without the prior written consent of MICHIGAN,
      such
      permission not to be unreasonably withheld or delayed. No
      assignment by LICENSEE will be effective until the intended assignee agrees
      in
      writing to accept all of the terms and conditions of this Agreement, and such
      writing is provided to MICHIGAN.

    


    14.11 MICHIGAN
      represents that it has, and will in the future, disclose to LICENSEE all
      licenses it has granted or may grant to third parties under PATENT RIGHTS and
      the scope of rights granted thereunder. 

    


    14.12 This
      Agreement supercedes all other previous agreements between MICHIGAN and LICENSEE
      concerning the PATENT RIGHTS.

    


    ********
This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

     

    
      
        
           

          


          
          

        

        
          -12-

          
            

          

        

        
          
          

          License
            Agreement between

          The
            University of Michigan and

          Quick-Med
            Technologies

          


        

      

    

    


    IN
      WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate
      originals by their duly authorized officers or representatives.

    


    


    FOR
      LICENSEE    FOR
      THE
      REGENTS OF THE

    UNIVERSITY
      OF MICHIGAN

    


    


    By /s/
      David Lerner  
 By /s/
      Kenneth J. Nisbet     

    (authorized
      representative)                    
      Kenneth J. Nisbet

                                                                                  
      Executive
      Director, UM Technology Transfer

    Typed
      Name:  David Lerner

    Title:    
      President     

    


    Date June
      1, 2007     Date May
      23,2007   

    


    


    


    *******
      This
      material has been omitted pursuant to a request for confidential treatment
      and
      filed separately with the Securities and Exchange Commission. 

    


    
      
        
          2

          


          
          

        

        
          -13-

          
            

          

        

        
          
          

          License
            Agreement between

          The
            University of Michigan and

          Quick-Med
            Technologies

          


        

      

    

    


    APPENDIX
      A-1 

    Page
      1

    
      	
              OTT
                File 1543 

              US
                6,683,069 

              CA
                2326507

              JP2000-541991

              MX
                009651

              KR
                7011003

              US
                7,141,238

            	
              OTT
                File 2115 

              US
                7,078,048

              US
                11/290,109 

              CA
                2446356

              MX
                2003/009995

            
	
              OTT
                File 1720 

              US
                10/167,040 (2003/0021816)

              US
                11/168,017 (2006/0009494)

              US
                11/169,072 (2005/0277695)

              EP
                1284721

            	
              OTT
                File 1175

              US
                5,837,224 

              JP
                3705820

              AU
                701132 

              CA
                2241981 

              MX
                208066 

              NZ
                330860 

              EP
                97903847.8

            
	
              OTT
                File 1967 

              US
                11/208,947 (2005/0281764)

              AU
                2001272028

              MX
                000089

              JP
                2002-504965

              HK
                03106899.6

            	
              OTT
                File 1356 

              US
                6,630,516 

              AU
                737376 

              EP
                1 005 333 

              US
                6,919,072

              MX
                997883

              IL
                131543

              JP
                537021/98

              CA
                2281944

              CN
                98803970.2

              FR/DE/GB
                1005333

               

            
	
              OTT
                File 2044 

              US
                09/740,242(2002/0119107)

              EP
                01985574.1

              AU
                2002235215

              CA
                2432265

              JP
                2002-550947

              MX
                005421

            	 


    

    


    


    


    


    


    


    


    


    


    


    


    


    
      
        
           

          


          
          

        

        
          -14-

          
            

          

        

        
          
          

          License
            Agreement between

          The
            University of Michigan and

          Quick-Med
            Technologies

          


        

      

    

    


    APPENDIX
      A-2

    


    


    


    OTT
      File 1442 

    US
      6,130,254 

    IL
      133194MX 9911052

    JP
      3554339

    CA
      2292600

    NZ
      501634


    NZ
      513045

    AU
      2002301116

    IN
      1184/MAS/98

    ZA
      98/4791 

    TW
      1234467

    US
      6,365,630 

    US
      6,942,870

    US
      10/948,002 (2005/0058709) 

    


    
      
        
           

          


          
          

        

        
          -15-

          
            

          

        

        
          
          

          License
            Agreement between

          The
            University of Michigan and

          Quick-Med
            Technologies